Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
What does it do?
Novo Nordisk is a Danish pharmaceutical company best known for making Ozempic and Wegovy — the wildly popular weight-loss and diabetes injections you've probably seen advertised or heard about in the news. They also make insulin, which millions of diabetics depend on daily to manage their blood sugar. Beyond diabetes and obesity, they have a smaller division making treatments for rare diseases like haemophilia, where blood doesn't clot properly. Think of them as the company that accidentally stumbled into one of the biggest drug categories in modern medicine.
Novo Nordisk sits at the centre of the obesity drug revolution — a market analysts estimate could be worth over $100 billion annually within a decade, as GLP-1 drugs like Wegovy are now being studied for heart disease, kidney disease, addiction, and even Alzheimer's. At its peak, Novo Nordisk briefly became the most valuable company in Europe, which tells you how seriously investors have taken this story. The question now is whether they can hold that lead as competition intensifies.
How does it make money?
Novo Nordisk makes money by selling prescription drugs directly to pharmacies, hospitals, and healthcare systems around the world. Their biggest earners are semaglutide-based products — Ozempic for type 2 diabetes and Wegovy for obesity — which together have driven revenue from around $290 billion DKK the prior year to $309 billion DKK most recently (note: figures are in Danish Krone, not US dollars). Insulin products like Tresiba and Victoza still contribute meaningfully, while the Rare Disease segment adds a smaller but stable revenue stream from specialised treatments.
Why do investors care?
The investment case rests on one big idea: obesity is a massive, undertreated global problem, and Novo Nordisk has a two-year head start on most rivals with proven, FDA-approved drugs. If GLP-1 drugs get approved for more conditions — cardiovascular disease approvals have already arrived — the addressable market grows dramatically. What has to go right is that Novo Nordisk keeps manufacturing capacity ahead of demand, maintains pricing power against insurers, and stays ahead of rivals like Eli Lilly. If those three things hold, revenue growth could continue for years.
Deep Dive
MemberA full investor briefing on Novo Nordisk A/S — history, leadership, risks, and outlook.